Pharmacokinetic Study of Busulfan in Allogeneic Stem Cell Transplantation in Adult Patients With Acute Leukemia
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Intravenous Busulfan (iv-Bu) is commonly used as part of preparation regimen for allogeneic
hematopoietic stem cell transplantation for patients with acute leukemia. Though the
pharmacokinetics data are available for population from America, Europe and Japan or Korea in
Asia, there are no data in Chinese population. It is shown that high Bu concentration are
associated with the toxicity such as veno-occlusion disease and lower concentration is
correlated with reduced anti-leukemia effect, thus the monitoring of Bu and/or the strategy
to achieve an optimal target Bu concentration are accepted to avoid toxicity while maintain
the anti-leukemia effect which may overall improve the outcome of allo-SCT. Thus we conduct
the pharmacokinetic study in Chinese population.